OPKO Health, Inc. to Post Q1 2025 Earnings of ($0.08) Per Share, HC Wainwright Forecasts (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for OPKO Health in a research note issued to investors on Wednesday, April 3rd. HC Wainwright analyst Y. Chen expects that the biotechnology company will post earnings of ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.07) EPS.

A number of other brokerages have also weighed in on OPK. Piper Sandler restated an “overweight” rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Barrington Research reiterated an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research report on Monday, April 1st.

OPKO Health Stock Down 0.7 %

Shares of NASDAQ OPK opened at $1.35 on Thursday. OPKO Health has a one year low of $0.85 and a one year high of $2.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22. The business’s fifty day moving average price is $1.02 and its 200-day moving average price is $1.26. The stock has a market capitalization of $940.94 million, a PE ratio of -5.40 and a beta of 1.82.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $181.90 million for the quarter, compared to analysts’ expectations of $177.53 million. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. The business’s revenue was down 1.9% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of OPKO Health by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company’s stock worth $60,024,000 after acquiring an additional 428,520 shares during the period. State Street Corp increased its position in shares of OPKO Health by 56.7% during the first quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock worth $95,250,000 after acquiring an additional 10,014,088 shares during the period. Geode Capital Management LLC increased its position in shares of OPKO Health by 3.9% during the second quarter. Geode Capital Management LLC now owns 8,742,614 shares of the biotechnology company’s stock worth $18,971,000 after acquiring an additional 331,968 shares during the period. Millennium Management LLC increased its position in shares of OPKO Health by 318.6% during the second quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock worth $18,698,000 after acquiring an additional 5,624,866 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of OPKO Health by 73.2% during the first quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company’s stock worth $24,717,000 after acquiring an additional 3,037,320 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Gary J. Nabel purchased 216,184 shares of the business’s stock in a transaction on Monday, January 8th. The shares were bought at an average cost of $0.93 per share, with a total value of $201,051.12. Following the transaction, the insider now owns 351,442 shares of the company’s stock, valued at $326,841.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Phillip Md Et Al Frost purchased 1,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were purchased at an average cost of $0.95 per share, with a total value of $950,000.00. Following the purchase, the chief executive officer now owns 204,968,225 shares of the company’s stock, valued at approximately $194,719,813.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary J. Nabel purchased 216,184 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was bought at an average cost of $0.93 per share, for a total transaction of $201,051.12. Following the completion of the purchase, the insider now directly owns 351,442 shares in the company, valued at approximately $326,841.06. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 6,907,715 shares of company stock valued at $6,585,090. Company insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.